Universidad de Navarra – Clínica Universidad de Navarra

LOGO CUN
clinica UNIVERSITARIA
clinica NIVERSITARIA

Laboratory

The Cellular Therapy Area (CTA) co-ordinates a multidisciplinary team of basic and clinical research in the CUN and CIMA around the therapeutic use of advanced therapy medicinal products (MTAs). CTA in collaboration with other centres is currently conducting several independent clinical trials with MTAs. These immunotherapy trials are conducted in the GMP (Good Manufacturing Practices) laboratory of the CTA. The laboratory operates under strict quality system that ensures compliance with GMP. GMP Laboratory has been authorised by the Government of Navarra for the production of idiotype autovaccines under good manufacturing practice in accordance with Royal Decree 288/1991 and in accordance with the provisions of Directive 89/342/EEC. The GMP laboratory has also certification that they work under GMP conditions by the Spanish Agency for Medicines and Health Products (AEMPS) according to the principles and guidelines of good manufacturing practice laid down in Directive 2003/94/EC for a total of 10 different MTA: skeletal myoblasts, autologous dendritic cells, mesenchymal cells derived from adipose tissue, mesenchymal cells derived from bone marrow, autologous CD133 cells, autologous endothelial progenitors derived from bone marrow, autologous epidermal sheets, limbocorneal cells, tumour infiltrating lymphocytes (TIL) and lymphokine activated killer (LAK). In the past 5 years the CTA group has participated as a producer laboratory in more than 20 clinical trials. In all these projects, the CTA group has been responsible for the validation of equipment and procedures and of the preparation of the therapeutic products under good manufacturing practice. In addition the group has actively participated in the design and development of the protocol of the clinical trial.

Staff enrolled in the project

  • Dr. Jose Luis Pérez Gracia
    Dr. Jose Luis Pérez GraciaConsultant

    +34 948 255 400

    He is Consultant Oncologist in the University of Navarra Clinic and Professor of Medicine in the University of Navarra. He leads the Clinical Research Unit in the Oncology Department. He has been Principal Investigator of more than 40 clinical and translational studies, and co‐authored more than 45 publications in peer‐reviewed journals, mainly in the field of Cancer Immunotherapy, Urological Cancers and predictive biomarkers. He coordinates the Translational Research Group of the Spanish Society of Medical Oncology (http://www.seom.org/git‐en) and belongs to the Executive Board of the Spanish Group of Research in Urological Cancer (SOGUG, http://www.sogug.es/).

  • Dr. Susana Inogés
    Dr. Susana InogésResearch Collaborator

    +34 948 255 400

    She received her MD degree at the University of Navarra in 1992 and the speciality in Immunology and her PhD degree at the same University in 1997. She is clinical collaborator in the Cell Therapy Area at the Clínica Universidad de Navarra. Her work is focused on the development of immunotherapy strategies for the cancer treatment, both active immunotherapy (idiotype vaccines in follicular lymphoma and dendritic cell vaccines in non-hematologic solid tumours) as passive immunotherapy. In this line, she is currently working in several clinical trials that are taking place at the Clínica Universidad de Navarra. Currently, she is responsible for the production of immunotherapy products that are prepared in the GMP laboratory for therapeutic use.

  • Dr. Carlos Alfaro Alegría
    Dr. Carlos Alfaro AlegríaResearch Collaborator

    +34 948 194 700 (Ext. 3032)

    He was licensed in Biology in the University of Navarra and in 2009 he obtained his doctorate in Biology. He is experienced in Gene Therapy and took place in a several oncology clinical trials in the Clínica Universidad de Navarra. He joined the Hepatology and Gene Therapy Division of CIMA in 2001.

  • Ascensión López Diaz de Cerio
    Ascensión López Diaz de Cerio

    PhD in Biology by the University of Navarra, she works as a researcher in the Area of Cell Therapy and in Departament of  Immunology-Immunotherapy  from University Hospital of Navarra. She is focused on the development of new strategies of immunotherapy for the treatment of cancer and diseases autoimmune as multiple sclerosis.

    He has collaborated on more than 15 research projects and in the implementation and development of 6 clinical trials at the University Hospital of Navarra, all focused on the combination of standard treatment for each type of tumor (chemotherapy, radiotherapy and / or surgery ) with immunotherapy strategies.

  • Carmen Oñate
    Carmen Oñate

    +34 948 194 700 ext 5016

    Carmen Oñate received her bachelor’s degree in Biology in 2009 from the University of Jaén.  The following year she earned her master’s degree in Immunology from the University of Barcelona and the Autonomous University of Barcelona under the direction of Dr. Eva Martínez Cáceres and Dr. Francesc E. Borrás. She joined Prof. Nacho Melero’s group in 2011 and ever since has been mainly focused on GMP grade dendritic cell vaccines production, the monitoring of clinical trials and biomarkers research.

  • Inma Rodriguez
    Inma Rodriguez

    +34 948 194700 Extensión: 3029

    Inma Rodríguez got her chemistry degree in University of Navarra. In 2007 she worked in LICA (Laboratorio Integrado de Calidad Ambiental) in Pamplona, monitoring enviroment pollution. In 2008 joined Prof. Melero’s group as a laboratory technician to work on cancer immunotherapy. Since then, she has been credited to work in GMP laboratories, she has collaborated in 6 research proyects and she is co-author of 8 publications in international journals.